论文部分内容阅读
目的探讨美罗培南对老年卒中相关性肺炎患者的临床治疗价值。方法选取2014年1月至2015年8月沈阳市第二中医医院收治的71例老年卒中相关性肺炎患者为研究对象,按随机数字表法将其分为对照组(35例)和观察组(36例)。对照组患者在常规治疗基础上给予头孢他啶,观察组患者在常规治疗基础上采用美罗培南进行治疗,比较两组患者治疗效果。结果观察组患者退热时间、咳嗽消失时间、湿性啰音消失时间、白细胞计数恢复正常时间、住院时间均明显短于对照组,差异均有统计学意义(均P<0.05);观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,观察组患者的生理功能、身体疼痛、总体健康、活力、情感职能、心理健康评分均明显高于对照组,差异均有统计学意义(均P<0.05)。结论采用美罗培南治疗老年卒中相关性肺炎临床疗效显著,可有效改善患者临床症状,提高生命质量,且安全性较高。
Objective To investigate the clinical value of Meropenem in elderly patients with stroke-associated pneumonia. Methods Seventy-one elderly patients with stroke-associated pneumonia admitted to the Second Hospital of Traditional Chinese Medicine from January 2014 to August 2015 in Shenyang were enrolled in this study. They were divided into control group (n = 35) and observation group (n = 36 cases). Patients in the control group were given ceftazidime on the basis of routine treatment. The patients in the observation group were treated with Meropenem on the basis of routine treatment, and the treatment effect was compared between the two groups. Results The observation group patients with fever, cough disappear time, wet rales disappear time, white blood cell count returned to normal time, hospitalization were significantly shorter than the control group, the difference was statistically significant (all P <0.05); observation group patients treatment The total effective rate was significantly higher than the control group, the difference was statistically significant (P <0.05); after treatment, the observation group patients physical function, physical pain, general health, vitality, emotional function, mental health scores were significantly higher than the control Group, the differences were statistically significant (all P <0.05). Conclusion The clinical efficacy of Meropenem in the treatment of senile stroke-associated pneumonia is significant, which can effectively improve the clinical symptoms, improve the quality of life, and have higher safety.